Changes In Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap
The Inflation Reduction Act of 2022 contained a provision that capped monthly out-of-pocket costs for insulin at $35 for people with Medicare, effective beginning 2023. This project evaluated changes in persistence to basal insulin among Medicare Advantage beneficiaries in the first year of this cost cap using the PQA Persistence to Basal Insulin measure that is used in Medicare Part D quality programs. Results of this project can inform policymakers, health plans, and other stakeholders seeking to better understand relationships between cost exposure and treatment persistence.